FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology and can be used in medicine. Invention discloses a composition containing a combination of three fused proteins: protein OspA with SEQ ID NO: 1 (LipS1D1-S2D1), protein OspA with SEQ ID NO: 2 (Lip-S4D1-S3hybD1) and protein OspA with SEQ ID NO: 3 (Lip-S5D1-S6D1).
EFFECT: composition according to the present invention can be used as a vaccine or as an immunomodulatory agent for inducing an immune response in a person against Lyme disease agents, in particular against bacteria of the genus Borrelia.
132 cl, 4 ex, 20 dwg, 15 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC OSPA GENES, PROTEINS AND THEIR APPLICATION METHODS | 2011 |
|
RU2773402C2 |
| ANTIGENIC POLYPEPTIDES BASED ON OSPA SEQUENCE | 2019 |
|
RU2816208C2 |
| IMMUNOGENIC FUSED PROTEIN | 2016 |
|
RU2757426C2 |
| POLYVALENT PNEUMOCOCCAL VACCINES | 2019 |
|
RU2815390C2 |
| METHODS FOR INCREASING VACCINE EFFICIENCY BY INJECTING IL-4R ANTAGONIST | 2017 |
|
RU2753869C2 |
| FUSION PROTEIN | 2016 |
|
RU2748643C2 |
| COMPOSITIONS WITH NEISSERIA MENINGITIDIS AND METHODS OF USING SAME | 2020 |
|
RU2839906C1 |
| VIRUS-LIKE PARTICLES WITH HIGH-DENSITY COATING FOR INDUCTION OF ANTIBODY EXPRESSION | 2017 |
|
RU2813282C2 |
| VACCINATION USING THE ALPHA 3 DOMAIN OF MICA/B FOR CANCER TREATMENT | 2016 |
|
RU2747296C2 |
| SAPOVIRUS VACCINES | 2022 |
|
RU2839769C2 |
